- A subcutaneous (SC) model of Merck’s (NYSE:MRK) blockbuster oncologic Keytruda (pembrolizumab) had been granted a U.S. FDA motion date of September 23.
- As well as, the European Medicines Company has accredited an extension software to introduce a brand new pharmaceutical kind and new
